{
    "nct_id": "NCT05222802",
    "official_title": "A Phase 1 Study to Evaluate the CNS-Penetrant EGFR/ERBB1 Inhibitor ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)",
    "inclusion_criteria": "* Age â‰¥ 18 years\n* Willing and able to give written informed consent\n* Diagnosis of Glioblastoma, IDH WT as defined by the WHO 2021 criteria\n* Adequate organ function\n* Willing to comply with all protocol-required visits, assessments, and procedures\n* Able to swallow oral medication\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "* Prior treatment with an EGFR inhibitor for Glioblastoma\n* Currently enrolled in another therapeutic study\n* History of clinically significant cardiovascular disease\n* Gastrointestinal conditions that may affect administration/absorption of oral medications\n* Have an active infection (bacterial, fungal, or viral) requiring systemic therapy\n* Pregnant or breastfeeding women\n* Any serious underlying medical or psychiatric condition or evidence of any other significant clinical disorder or laboratory finding that renders the patient inappropriate to participate in the study\n* Known allergies, hypersensitivity, or intolerance to ERAS-801 or its excipients",
    "miscellaneous_criteria": ""
}